Median survival:Control/anti-OX40/IRE: 22/24/51 days. IRE + anti-OX40: 80% were alive at 120 days (median survival not reached). Increased tumor infiltration of CD8+ T cells and decreased MDSCs, as well as higher levels of IFN-γ and TNF-α compared to IRE alone. Secondary, non-treated tumor, median survival:Control/anti-OX40/IRE: 21/21/31 days, respectively. IRE + anti-OX40: 44 days. The gene discussed is CD8A; the disease is neoplasm.